Biotechnology
Appendix 4C - Q1 FY22 Quarterly Cash Flow Report
Highlights: * New details on ATH34 Phase 2 clinical trial released. * Data from bioMUSE presented at International Parkinson and Movement Disorder Society Congress. * Expanded intellectual property portfolio positions future opportunities. * Cash balance as of 30 September 2021 of A$41.3M....
2021-10-29 14:50
2036
/DISREGARD RELEASE: Frontier Biotechnologies/
We are advised by Frontier Biotechnologies that journalists and other readers in Malaysia should disregard the news release, "Frontier Biotechnologies' Long-acting Injectable (Aikening(R)), In A Two Drug Regimen, Proves Safe And Effective For Critically Ill Hospitalized AIDS Patients", issued onOc...
2021-10-29 13:34
1500
EZZ Marks Transition to Genomic Health Following Exceptional FY21 Performance
About EZZ Life Science Holdings EZZ Life Science Holding Limited (ASX:EZZ) is a genomic life science company with a mission to improve quality of life and human health. EZZ has a focus on genomic research and development to address four key human health challenges: genetic longevity, human papi...
2021-10-29 04:05
3362
Aiming for Global CDMO, Xcell Therapeutics opens an export route to 62 countries with cell therapy culture technology.
SEOUL, South Korea, Oct. 28, 2021 /PRNewswire/ -- In a hair follicle, there are "dermal follicle papilla cells" that appear 3,000 grapes clustered together. The name was given because its outline resembles the papilla of the human body when observed under a microscope. Hair loss occurs when der...
2021-10-28 21:00
1061
Merck Drives New Innovation & Adds Capacity to Advance Next Generation Antibody-drug Conjugate (ADC) Therapies
- Merck's unique technology, ChetoSensar™, gives new promise to ADCs by alleviating solubility challenges - New DOLCORE™ platform increases speed-to-market by up to a year - Expanded ADC clinical manufacturing facility drives next generation ADCs, building on company's 15 years of ADC Contract...
2021-10-28 21:00
2268
HanAll Biopharma Reports Third Quarter 2021 Results
* Q3'21 sales of KRW 25.5 billion increased 15% from the same period last year * Q3'21 operating profit of KRW 2.2 billion grew by 120% compared to Q3'20 * Nine months sales of KRW 76.7 billion and operating profit of KRW 9.2 billion rose by 15% and 67% YoY, repectively SEOUL, South Korea, Oct...
2021-10-28 21:00
1267
BioVaxys Further Expands Intellectual Property Portfolio in Global Markets
- Files Applications for International Patent and Trademark Protection of CoviDTH VANCOUVER, BC, Oct. 28, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV), (FRA: 5LB), (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that it has broadened the patent coverage on CoviDTH, its T ...
2021-10-28 20:00
2479
Interim report for Q3 2021 : Bactiguard Holding AB (publ)
STOCKHOLM, Oct. 28, 2021 /PRNewswire/ -- Capital injection initiates a new phase of accelerated expansion Third quarter (July-September 2021) * Revenues amounted to SEK 45.2 (34.1) million, an increase of 32%. Adjusted for currency effects revenues increased by 36%. * EBITDA amounted to SEK ...
2021-10-28 15:23
1442
WuXi Biologics Completes GMP Inspection by Health Canada for Drug Substance Facility
- Successfully completed nearly 20 regulatory inspections in total, including 13 regulatory inspections since the start of 2021 WUXI, China, Oct. 27, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced th...
2021-10-28 08:30
1766
Frontier Biotechnologies' Long-acting Injectable (Aikening(R)), In A Two Drug Regimen, Proves Safe And Effective For Critically Ill Hospitalized AIDS Patients
LONDON, Oct. 27, 2021 /PRNewswire/ -- Frontier Biotechnologies today shared real-world evidence of Albuvirtide (ABT)-based two drug regimen's safety and efficacy for hospitalized AIDS patients at the European AIDS Clinical Society (EACS) Conference. Observations from a single-center, retrospec...
2021-10-27 22:08
1281
Frontier Biotechnologies' Long-acting Injectable (Aikening(R)), In A Two Drug Regimen, Proves Safe And Effective For Critically Ill Hospitalized AIDS Patients
LONDON, Oct. 27, 2021 /PRNewswire/ -- Frontier Biotechnologies today shared real-world evidence of Albuvirtide (ABT)-based two drug regimen's safety and efficacy for hospitalized AIDS patients at the European AIDS Clinical Society (EACS) Conference. Observations from a single-center, retrospec...
2021-10-27 22:06
1277
Frontier Biotechnologies' Long-acting Injectable (Aikening(R)), In A Two Drug Regimen, Proves Safe And Effective For Critically Ill Hospitalized AIDS Patients
LONDON, Oct. 27, 2021 /PRNewswire/ -- Frontier Biotechnologies today shared real-world evidence of Albuvirtide (ABT)-based two drug regimen's safety and efficacy for hospitalized AIDS patients at the European AIDS Clinical Society (EACS) Conference. Observations from a single-center, retrospec...
2021-10-27 22:03
1387
Frontier Biotechnologies' Long-acting Injectable (Aikening(R)), In A Two Drug Regimen, Proves Safe And Effective For Critically Ill Hospitalized AIDS Patients
LONDON, Oct. 27, 2021 /PRNewswire/ -- Frontier Biotechnologies today shared real-world evidence of Albuvirtide (ABT)-based two drug regimen's safety and efficacy for hospitalized AIDS patients at the European AIDS Clinical Society (EACS) Conference. Observations from a single-center, retrospec...
2021-10-27 21:25
1140
Frontier Biotechnologies' Long-acting Injectable (Aikening(R)), in a Two Drug Regimen, Proves Safe and Effective for Critically Ill Hospitalized AIDS Patients
LONDON, Oct. 27, 2021 /PRNewswire/ -- Frontier Biotechnologies today shared real-world evidence of Albuvirtide (ABT)-based two drug regimen's safety and efficacy for hospitalized AIDS patients at the European AIDS Clinical Society (EACS) Conference. Observations from a single-center, retrospec...
2021-10-27 20:47
969
Novavax Files for Authorization of its COVID-19 Vaccine in the United Kingdom
* Filing marks first protein-based COVID-19 vaccine submitted to MHRA for authorization * All modules required for regulatory review, including CMC data, are now complete * Submission based on Phase 3 data from ~45K patients demonstrating high efficacy and well-tolerated safety, including a...
2021-10-27 20:30
2206
Abcam completes $340m strategic acquisition and expands kit capacity and capability
- Completing $340m strategic acquisition of BioVision
- Expanding facilities in Eugene, further growing kits and assays portfolio
- Supporting the growing demand of the sector and accelerating execution of
strategic plan
CAMBRIDGE, England, Oct. 27, 2021 /PRNewswire/ -- Abcam
2021-10-27 14:00
2720
I-Mab Announces Strategic Partnership with Sinopharm in Preparation for Launch of its Innovative Assets in China
* I-Mab strategic partnership with Sinopharm will covers all aspects of the go-to-market process, including authorization of more than 300 Sinopharm's subsidiaries as distributors acrossChina. * I-Mab is on track to submit BLA for third line multiple myeloma (MM) treatment by Q4 2021. * The...
2021-10-26 20:00
1758
Samsung Biologics Reports Third Quarter 2021 Financial Results
* Q3'21 revenue of KRW 450.7 billion increased 64% compared to Q3'20. * Q3'21 operating profit of KRW 167.4 billion increased 196% compared to Q3'20. * Stable supply, strong operational excellence and a high utilization rate across all plants. * Active investment on expansion, pre-sales ac...
2021-10-26 15:23
1504
Angel Pharmaceuticals Announces Approval of IND Application in China for ITK Inhibitor CPI-818
JIAXING, China and BURLINGAME, Calif., Oct. 25, 2021 /PRNewswire/ -- Angel Pharmaceuticals Co., Ltd. ("Angel Pharma") today announced that its IND application for CPI-818, a small molecule ITK inhibitor, has been approved by the Center for Drug Evaluation (CDE) to initiate clinical trials in pati...
2021-10-26 07:30
1159
SCN9A Antisense Pain Killer OLP-1002 Moves into Phase 2a Stage
SEOUL, South Korea, Oct. 25, 2021 /PRNewswire/ -- OliPass Corporation, a South Korea based biotech specialized in the development of RNA therapeutics, announced to initiate a Phase 2a trial for SCN9A antisense pain killer OLP-1002 inAustralia. In the Phase 2a trial of a two stage adaptive design ...
2021-10-25 20:30
1422
Week's Top Stories
Most Reposted
Another 'Reason to Travel': Agoda and Singapore Tourism Board Renew Partnership to Boost Travel to Singapore
[Picked up by 350 media titles]
2024-06-19 11:00
MIFB 2024 ENLISTS F&B EXPERTS TO SPEAK ON THE LATEST IN INDUSTRY TRENDS AND THE FUTURE OF FOOD
[Picked up by 335 media titles]
2024-06-20 16:24
New Study Finds Cybersecurity as Top Concern Among Automotive Manufacturers
[Picked up by 317 media titles]
2024-06-19 08:05k-ID Closes $45 Million Series A from Andreessen Horowitz and Lightspeed Venture Partners to Set a New Global Benchmark for Age-appropriate Gaming Experiences
[Picked up by 316 media titles]
2024-06-25 21:00
THEIR ROYAL HIGHNESSES THE DUKE AND DUCHESS OF EDINBURGH CELEBRATE THE GRAND OPENING OF THE PENINSULA LONDON, BELGRAVIA
[Picked up by 313 media titles]
2024-06-19 11:38
Most Read
Another 'Reason to Travel': Agoda and Singapore Tourism Board Renew Partnership to Boost Travel to Singapore
2024-06-19 11:00
15576
MIFB 2024 ENLISTS F&B EXPERTS TO SPEAK ON THE LATEST IN INDUSTRY TRENDS AND THE FUTURE OF FOOD
2024-06-20 16:24
13163
New Study Finds Cybersecurity as Top Concern Among Automotive Manufacturers
2024-06-19 08:05
9412
